Phil Newman

About

Editor-in-Chief Phil is Editor-in-Chief Longevity.Technology and founder of Crowd Longevity a digital investment platform for international investors and Longevity start-ups launching in 2020.

In his career, Phil has held c-level management positions; applying his marketing and business development expertise into these tech sectors: Longevity; IoT; AI; Medical Devices; Biopharma; 3D Manufacturing; Smartgrid and Sustainability.
127 POSTS

/

0 COMMENTS

Articles

Neurotech2020: It’s a brave new world

It's an online conference, but not as you know it. Say goodbye to Zoom fatigue and hello to Neurotech2020. Understanding the brain, consciousness and thought...

Longevity big-hitters join our current investment round

Some news of our own: Key investors join the First Longevity funding round. Among those participating in this second stage funding for First Longevity are...

Journalism Matters Week: We’re doing our bit!

2020 has been an incredible year. For journalists, and a huge number of other professions, it has been one of the biggest periods of...

Startup Showcase: Rejuvenate Biomed: What do you think?

Rejuvenate Biomed are ready to take their first Longevity therapy into clinical trials: Invest, buy, or both? It's time to have your say on...

Exclusive video interview with Dave Asprey

We talk supplementation, neurotech, mitochondrial dysfunction, clinical scale-ups, COVID and CGM with Longevity legend: Dave Asprey Ahead of Revolution Against Aging and Death conference, which...

Startup Showcase: Jinfiniti: What do you think?

Comprehensive biomarker tech: Invest, buy, or both? It's time to have your say on Jinfiniti. We like what Jinfiniti are doing; but that's just our...

Elysium publishes positive results from two studies for Basis

Encouraging news from Elysium Health illustrates that the Longevity supplements market is building clinical and commercial traction. In December 2019, Elysium announced a $40m Series...

Help us help you: Longevity biotech survey

A new survey on translational processes and hurdles to clinical trials in Longevity biotech. We're working with two MDs: Oliver Zolman and Jian Fransen, on...

First Longevity announces first investors for current round

Some news of our own: European VC fund and a Longevity innovator participate in the First Longevity funding round. Last week we announced that Tom...